Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Kamada Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₪21.63 |
52 Week High | ₪23.38 |
52 Week Low | ₪16.85 |
Beta | 0.24 |
11 Month Change | 15.24% |
3 Month Change | 9.02% |
1 Year Change | 17.55% |
33 Year Change | 20.50% |
5 Year Change | 10.02% |
Change since IPO | 64.49% |
Recent News & Updates
Recent updates
Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality
Mar 14Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%
Dec 30Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year
Dec 22Is Kamada (TLV:KMDA) Using Too Much Debt?
Jan 26We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed
Dec 16Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%
Mar 01Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders?
Feb 08Is Weakness In Kamada Ltd. (TLV:KMDA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Jan 21Kamada Ltd. (TLV:KMDA) Shares Could Be 42% Below Their Intrinsic Value Estimate
Jan 03How Many Kamada Ltd. (TLV:KMDA) Shares Have Insiders Sold, In The Last Year?
Dec 15Are Kamada's (TLV:KMDA) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 29Shareholder Returns
KMDA | IL Biotechs | IL Market | |
---|---|---|---|
7D | 3.9% | -1.1% | -1.2% |
1Y | 17.6% | -5.6% | -1.9% |
Return vs Industry: KMDA exceeded the IL Biotechs industry which returned -5.6% over the past year.
Return vs Market: KMDA exceeded the IL Market which returned -1.9% over the past year.
Price Volatility
KMDA volatility | |
---|---|
KMDA Average Weekly Movement | 4.1% |
Biotechs Industry Average Movement | 8.1% |
Market Average Movement | 4.4% |
10% most volatile stocks in IL Market | 7.4% |
10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: KMDA has not had significant price volatility in the past 3 months.
Volatility Over Time: KMDA's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 378 | Amir London | www.kamada.com |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.
Kamada Ltd. Fundamentals Summary
KMDA fundamental statistics | |
---|---|
Market cap | ₪1.21b |
Earnings (TTM) | ₪46.47m |
Revenue (TTM) | ₪557.80m |
26.8x
P/E Ratio2.2x
P/S RatioIs KMDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KMDA income statement (TTM) | |
---|---|
Revenue | US$149.55m |
Cost of Revenue | US$89.14m |
Gross Profit | US$60.40m |
Other Expenses | US$47.94m |
Earnings | US$12.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.22 |
Gross Margin | 40.39% |
Net Profit Margin | 8.33% |
Debt/Equity Ratio | 0% |
How did KMDA perform over the long term?
See historical performance and comparison